Table 1.
Studies on the clinical importance of the expression of genes abcb1, abcc1, and lrp and/or proteins ABCB1, ABCC1, and LRP in ALs
| Author | Method | Sample | Results/conclusions |
|---|---|---|---|
| Dhooge et al. (1999) 74 | Immunohistochemistry | de novo ALL (n = 102) and relapse ALL (n = 35) | The expression of protein ABCB1 negatively influenced the prognosis, especially in de novo ALL cases |
| Wutcher et al. (2000) 75 | Flow cytometry | ALL (n = 102) and AML (n = 121) | The expression of protein ABCB1 did not negatively influence the prognosis |
| Fujimaki et al. (2002) 73 | Flow cytometry and RT‐PCR | ALL (n = 18) and AML (n = 26) | The expression of gene and protein ABCB1 was more significant in AML patients, mainly in relapse cases. The expression of protein ABCC1 did not show clinical correlation |
| Schaich et al. (2004) 76 | RT‐PCR | De novo or secondary AML (n = 331) | The expression of ABCB1 and ABCC1 negatively influenced full disease remission after treatment, while LRP did not negatively influence the prognosis |
| Suarez et al. (2004) 77 | Flow cytometry | De novo AML (n = 90) | The expression of ABCB1, ABCC1, and LRP did not negatively influence the prognosis |
| Valera et al. (2004) 78 | RT‐PCR | ALL (n = 30) | Among the evaluation of proteins ABCB1, ABCC1, and LRP, only LRP negatively influence the prognosis |
| Benderra et al. (2005) 79 | Flow cytometry | De novo AML (n = 85) | The expression of ABCB1 was shown to influence treatment failure |
| Olson et al. (2005) 80 | Flow cytometry | Initial ALL (n = 295) | The overexpression of ABCB1, ABCC1, and LRP to diagnostics did not influence treatment failure |
| Anuchapreeda et al. (2006) 81 | RT‐PCR | ALL (n = 61) and AML (n = 14) | The expression of gene abcb1 was statistically similar in patients with relapse and patients who responded to treatment |
| Huh et al. (2006) 82 | Nested RT‐PCR | ALL (n = 32) and AML (n = 39) | The expression of ABCB1, ABCC1, and LRP influenced full remission and the survival rate in AL patients, especially ABCB1 and LRP |
| Styczynski et al. (2007) 83 | Flow cytometry | Initial ALL (n = 527), relapse ALL (n = 104), initial AML (n = 133), and relapse AML (n = 23) | The expression of ABCB1, ABCC1, and LRP represented an adverse prognostic factor with relevance in de novo ALL cases |
| Yasunami et al. (2007) 64 | Flow cytometry and real‐time RT‐PCR | ALL‐T (n = 11) | Among the evaluation of proteins ABCB1, ABCC1, and LRP, only LRP showed increased expression and function |
| Fedasenka et al. (2008) 84 | Real‐time RT‐PCR | Pre‐B ALL with differentiated responses to CT (n = 19) | The expression of ABCC1 and LRP did not have a direct relation with minimum residual disease |
| Figueiredo‐pontes et al. (2008) 85 | Flow cytometry | De novo AML CD34+ (n = 26) | The overexpression of ABCB1, ABCC1, and LRP in more immature leukemia cell strains influenced treatment failure |
| Grotel et al. (2008) 86 | Flow cytometry and real‐time RT‐PCR | ALL‐T (n = 72) | The expression of ABCB1, ABCC1, and LRP to diagnosis, in all cut‐offs adopted, did not negatively influence prognosis |
| Svirnovski et al. (2009) 87 | Flow cytometry and RT‐PCR | ALL (n = 65), relapse ALL (n = 42), AML (n = 53), and relapse AML (n = 16) | There was no significant difference between the expression of gene abcb1 and protein ABCB1 in patients with de novo and recently diagnosed AL |
| El‐Sharnouby et al. (2010) 88 | RT‐PCR | All (n = 34) | The expression of ABCC1 and LRP were associated with poorer outcomes and worse two‐year survival |
| Chauhan et al. (2012) 89 | Real‐time RT‐PCR | ALL (n = 40) and AML (n = 45) | High expression of ABCB1 in AML and ABCC1 in ALL was associated with poor response to induction chemotherapy |
| Scheiner et al. (2012) 90 | Flow cytometry | AML (n = 109) | ABCB1 expression did not show an impact on the response to remission induction therapy |
ALL, acute lymphoblastic leukemia; ALL‐T, acute lymphoblastic leukemia of lymphocytes T; Pre‐B ALL, acute lymphoblastic leukemia of pre‐B lymphocytes; AML, acute myeloid leukemia; CT, chemotherapy; RT‐PCR, reverse transcriptase–polymerase chain reaction.